CL

Business profile & competitive position

Colgate-Palmolive Company is a Consumer Defensive stock in the Household & Personal Products industry. It operates through two segments: Oral, Personal and Home Care (toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners) and Hill’s Pet Nutrition (specialty dog and cat foods). The company sells in more than 200 countries and territories through retailers, wholesalers, eCommerce retailers, veterinarians and certain direct-to-consumer channels. In 2025, Oral Care represented 44% of worldwide net sales, Pet Nutrition 23%, Personal Care 17% and Home Care 16%.

The $68.9 billion market cap and 9.7% net margin fit the profile of a mature, brand-heavy consumer staples operator. The 631.1% ROE, however, is extraordinarily high—far above what product pricing power alone usually produces. Such a figure generally signals a leveraged or heavily shrunken equity base, often the result of share buybacks, debt-funded returns or accounting factors, rather than pure operational superiority. That means the headline return should be read alongside capital-structure detail, not as a standalone moat metric. The 0.32 beta confirms the stock’s defensive character, indicating it has historically moved much less than the overall market.

Financial posture

CL commands a P/E of 33.9 on a $68.9 billion market capitalization. That multiple leaves little room for error and sits at a premium to many staples peers, implying the market is paying up for earnings consistency, low volatility and exposure to pet-nutrition growth. The 9.7% net margin is healthy for a packaged-goods company, while the 631.1% ROE again points to balance-sheet structure rather than margin dominance. Investors interpreting the valuation should weigh the premium multiple against the 0.32 beta: the stock may hold up in turbulent markets, but it can also lag when risk appetite surges.

Strategic priorities & outlook

Colgate-Palmolive’s most recent SEC 10-K filing lays out four operational priorities. First, drive organic sales growth and deliver consistent, compounded earnings-per-share growth. Second, achieve operational efficiencies while growing free cash flow and using the balance sheet efficiently. Third, leverage global brand reach, science-based innovation, an agile supply chain and best-in-class omni-channel demand generation. Fourth, build capabilities in data, analytics and artificial intelligence and evolve a high-impact, inclusive culture.

The filing also provides useful concentration and footprint context. Walmart and its affiliates accounted for approximately 11% of 2025 net sales; no other customer exceeded 10%. As of December 31, 2025, Colgate-Palmolive employed roughly 33,600 people across more than 100 countries, with over 84% located outside the United States. That geographic footprint magnifies the importance of international demand, local marketing and currency translation.

Macro & geopolitical exposure

Because Colgate-Palmolive sits in Household & Personal Products, its exposures are those typical of global consumer staples companies. Currency translation is a major factor, with the majority of its workforce and revenue tied to non-U.S. markets. A stronger U.S. dollar can dampen reported overseas earnings even when local operations remain healthy. Input-cost inflation—resins, surfactants, palm derivatives, pet-food proteins and packaging—can squeeze gross margins if price hikes lag cost moves. Trade policy matters as well; tariffs on raw materials or finished goods can raise costs or disrupt regional pricing strategies. Regulatory oversight of ingredients, product claims, labeling and packaging waste applies across all four categories, and consumer shifts toward natural, sustainable and science-backed formulations can reshape brand loyalty. Demographic trends, including pet humanization and oral-care premiumization, offer mix opportunities but also attract new entrants.

Recent developments

Recent headlines have centered on dividend durability, rate sensitivity and product innovation. On September 27, 2026, 247wallst.com asked whether Colgate-Palmolive’s dividend streak dating back to 1895 still deserves investor capital. On September 24, 2026, fool.com included CL among dividend stocks to buy and hold even if the Federal Reserve keeps raising interest rates. On September 23, 2026, zacks.com highlighted Colgate-Palmolive as a strong growth stock. The same day, PR Newswire reported that Tom’s of Maine introduced a hydroxyapatite toothpaste to meet rising consumer demand. None of these items amount to company guidance, but together they reflect market interest in income reliability, interest-rate resilience and innovation-led oral-care expansion.

Earnings behavior & post-earnings drift

Colgate-Palmolive has beaten earnings estimates in all eight of the most recent reported quarters, translating to a 100% beat rate with an average earnings surprise of 3.3%. Across those same eight quarters, the average 5-day price move after the report was 2.32% to the upside, classified as an “up” drift. That pattern suggests the market has generally treated the releases favorably over the short term, even when the immediate next-day reaction was negative.

The last four reports illustrate that two-step dynamic. On July 31, 2026, CL reported EPS of $0.99 versus a $0.947 estimate, a 4.5% beat; the stock fell 1.56% the next day but gained 2.16% over the following five sessions. On May 1, 2026, EPS came in at $0.97 against $0.943, a 2.9% beat, with a next-day drop of 2.17% turning into a five-day gain of 0.33%. On January 30, 2026, EPS of $0.95 beat the $0.912 estimate by 4.2%, producing a 1.77% next-day gain and a 4.56% five-day gain. On October 31, 2025, EPS of $0.91 beat the $0.889 estimate by 2.4%; the stock dropped 2.69% the next day but recovered to post a 2.22% gain over the next five trading days.

The unofficial consensus for the upcoming October 30, 2026 report, scheduled before the market open, stands at $0.92 per share. As of the current snapshot, CL trades at $86.15, with an RSI of 39.1 and a 50-day EMA of $89.12, leaving the price slightly below its short-term moving average heading into the print.

For a deeper dive into how sell-side analysts currently view CL—including rating distributions, consensus revisions and the latest institutional commentary—investors can review the full institutional verdict on the platform.